Back to Newsroom

Pharnext’s Pleotherapy Shows Synergistic Effects with PXT-864 in Alzheimer’s Disease through Preclinical Data Published in Nature’s Scientific Reports

PARIS, Jan. 8, 2015 – Pharnext SAS today announced the publication of preclinical results in Nature’s Scientific Reports for its lead pleodrug, PXT-864, in Alzheimer’s disease. These data further validate its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases.

Click here to read more